-+ 0.00%
-+ 0.00%
-+ 0.00%

TransCode Therapeutics to Present TTX-MC138 Phase 1a Trial Data at ESMO 2026

PUBT·10/19/2026 12:17:12
Listen to the news
TransCode Therapeutics to Present TTX-MC138 Phase 1a Trial Data at ESMO 2026
  • TransCode Therapeutics will present Phase 1a results for TTX-MC138 at ESMO Congress in Madrid, Spain, on October 23, 2026.
  • The trial evaluates its lead drug candidate in patients with advanced solid tumors. TTX-MC138 targets miR-10b, a microRNA associated with metastatic progression.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE74368) on October 19, 2026, and is solely responsible for the information contained therein.